Bronchitol® is a precision spray‐dried form of mannitol that is delivered to the lungs by a specially designed, portable inhaler. Bronchitol® improves lung function and helps to clear mucus from the lungs in patients suffering from cystic fibrosis. Patients are required to pass a tolerance test prior to being prescribed Bronchitol® to ensure that they are not hyperresponsive to mannitol.
Bronchitol® has already been commercialized in 14 countries. EffRx has an exclusive license agreement with Pharmaxis Ltd, a listed pharmaceutical research company in Australia, for the registration and commercialization of Bronchitol® for cystic fibrosis in Switzerland. Swissmedic has approved Bronchitol® (inhaled mannitol) for the treatment of cystic fibrosis (CF) in adults and in children aged 6 years and above as add‐on to other medicines.
To visit the international Bronchitol website click here